

SUPP. TABLE 1. Demographics and clinical ratings of subject groups.

Clinical Measures	Healthy Controls (n=44)	Schizophrenics (n=49)	Medicated Controls (n=20)	p ^a	p ^b	p ^c
Gender (M/F)	29/15	33/16	5/15			
Age (Mean ± S.D.)	36.7 ± 7.8	38.2 ± 10.6	34.75 ± 8.6	n.s.	n.s.	n.s.
Body Mass Index (BMI)	26.1 ± 5.2	30.8 ± 6.9	32.0 ± 7.0	<0.01	<0.01	n.s.
Antipsychotic dosed (Mean ± S.D.)		570 ± 430	300 ± 185			<0.01
Benzodiazepines (Number of Subjects)		10	5			
Antidepressants (Number of Subjects)		22	7			
Mood stabilizers (Number of Subjects)		11	3			
PANSS Positive (Mean ± S.D.)		21.5 ± 4.2				
PANSS Negative (Mean ± S.D.)		22.3 ± 4.8				
PANSS General (Mean ± S.D.)		45.2 ± 6.9				
PANSS Total (Mean ± S.D.)		88.5 ± 12.7				

^a One-way ANOVA followed by post-hoc two-tailed unpaired t-test between healthy and schizophrenia groups.

^b One-way ANOVA followed by post-hoc two-tailed unpaired t-test between healthy and medicated control groups.

^c One-way ANOVA followed by post-hoc two-tailed unpaired t-test between schizophrenia and medicated control groups.

^d Chlorpromazine equivalents (mg/day).